Sionna Therapeutics, Inc. 8K

Sionna Therapeutics reported that its CF candidate SION-719 failed a Phase 2a proof‑of‑concept endpoint and will not be advanced as an add‑on to Trikafta, while a Phase 1 trial of SION-451 dual combinations met safety/PK objectives and the company is evaluating next steps and capital-preservation measures.

On August 10, 2026, Sionna Therapeutics, Inc. announced topline results from two cystic fibrosis development programs, reporting that its Phase 2a PreciSION CF proof‑of‑concept trial of SION-719 as an add‑on to Trikafta failed to meet the key activity endpoint of sweat chloride reduction, leading the company to discontinue further development of SION-719 as an add‑on therapy, while its Phase 1 trial of SION-451 dual combinations in healthy volunteers met safety, tolerability and pharmacokinetic goals and identified SION-451 plus SION-2222 as the preferred combination; the company is reassessing next steps for the SION-451 program and plans to take capital-preservation actions after ending Q2 with approximately $268.3 million in cash, cash equivalents and marketable securities.

Filing Facts

CIK

2036042

Ticker

SION

Form

8K

Source Type

fda

Accession

0001193125-26-341230

Alert Tier

7